Literature DB >> 19959240

Different profile of substance abuse in relation to predominant polarity in bipolar disorder: The Vitoria long-term follow-up study.

Ana González-Pinto1, Susana Alberich, Sara Barbeito, Marta Alonso, Eduard Vieta, Anabel Martínez-Arán, Margarita Saenz, Purificación López.   

Abstract

BACKGROUND: There is a need for comparisons of long-term outcomes in bipolar disorder patients with predominantly manic symptoms vs. predominantly depressive symptoms, especially the course of comorbid alcohol/substance abuse.
METHOD: A naturalistic sample of bipolar I patients (n=120) was followed prospectively for up to 10years. At baseline, number and polarity of past episodes were used to classify patients as predominantly manic or predominantly depressive if there were more manic or more depressive episodes, respectively. 25 patients were excluded from the analyses. Outcomes including episodes, hospitalisations and suicide attempts were recorded at bimonthly visits. Mixed effects models compared the course of alcohol and other substance abuse in predominantly manic vs. depressive patients.
RESULTS: Of the 95 patients analyzed, 44 (46.3%) had predominantly manic episodes and 51 (53.7%) had predominantly depressive episodes. At baseline, the predominantly depressive group had more history of suicide attempts (45.1% vs. 20.5%; p=0.021) and more family history of affective disorders (64.7% vs. 38.6%; p=0.020), but they had fewer previous hospitalisations than the manic group (mean 0.38 vs. 0.50; p=0.025). During the 10-year follow-up, the predominantly depressive group was associated with more episodes (p=0.001), more hospitalisations (p=0.004) and more suicide attempts (p=0.002). At baseline, there were no differences between the manic and depressive groups in the frequency of alcohol abuse (43.2% and 35.3%, p=0.565) or other substance abuse (13.6% and 9.8%, p=0.794). During the 10-year follow-up, the frequency of alcohol and other substance abuse decreased significantly in the manic group only, after controlling by age at onset and civil (marital) status.
CONCLUSION: Long-term clinical outcomes differ between predominantly manic vs. depressive bipolar patients, with the predominantly depressive group having a worse prognosis and maintained alcohol and other substance abuse. These differences should be considered when designing treatment approaches for bipolar patients with comorbid alcohol/substance abuse. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19959240     DOI: 10.1016/j.jad.2009.11.005

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  12 in total

Review 1.  New ways to classify bipolar disorders: going from categorical groups to symptom clusters or dimensions.

Authors:  Chantal Henry; Bruno Etain
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

2.  Substance use disorders in adolescent and young adult relatives of probands with bipolar disorder: What drives the increased risk?

Authors:  Leslie A Hulvershorn; Jennifer King; Patrick O Monahan; Holly C Wilcox; Philip B Mitchell; Janice M Fullerton; Howard J Edenberg; Gloria M P Roberts; Masoud Kamali; Anne L Glowinski; Neera Ghaziuddin; Melvin McInnis; Priya A Iyer-Eimerbrink; John I Nurnberger
Journal:  Compr Psychiatry       Date:  2017-07-27       Impact factor: 3.735

3.  Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes.

Authors:  Manuel Martin-Carrasco; Ana Gonzalez-Pinto; Jaime L Galan; Javier Ballesteros; Jorge Maurino; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2012-03-10       Impact factor: 3.455

4.  Predominant polarity in bipolar disorder and validation of the polarity index in a German sample.

Authors:  Julia Volkert; Kathrin C Zierhut; Miriam A Schiele; Martina Wenzel; Juliane Kopf; Sarah Kittel-Schneider; Andreas Reif
Journal:  BMC Psychiatry       Date:  2014-11-22       Impact factor: 3.630

Review 5.  Treatment implications of predominant polarity and the polarity index: a comprehensive review.

Authors:  Andre F Carvalho; João Quevedo; Roger S McIntyre; Márcio G Soeiro-de-Souza; Konstantinos N Fountoulakis; Michael Berk; Thomas N Hyphantis; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

6.  Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study.

Authors:  Angelo Giovanni Icro Maremmani; Silvia Bacciardi; Luca Rovai; Fabio Rugani; Enrico Massimetti; Denise Gazzarrini; Liliana Dell'Osso; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2014-12-12       Impact factor: 3.390

7.  Who's the Leader, Mania or Depression? Predominant Polarity and Alcohol/Polysubstance Use in Bipolar Disorders.

Authors:  Delfina Janiri; Marco Di Nicola; Giovanni Martinotti; Luigi Janiri
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

Review 8.  Predominant Polarity in Bipolar Affective Disorder: A Scoping Review of Its Relationship with Clinical Variables and Its Implications.

Authors:  Arghya Pal
Journal:  Indian J Psychol Med       Date:  2019 Jan-Feb

9.  Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.

Authors:  Masoud Kamali; Samantha Pegg; Jessica A Janos; William V Bobo; Benjamin Brody; Keming Gao; Terence A Ketter; Susan L McElroy; Melvin G McInnis; Dustin J Rabideau; Noreen A Reilly-Harrington; Richard C Shelton; Louisa G Sylvia; Mauricio Tohen; Andrew Nierenberg
Journal:  J Psychiatr Res       Date:  2021-06-02       Impact factor: 5.250

10.  Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.

Authors:  Ana González-Pinto; Itxaso González-Ortega; Susana Alberich; Sonia Ruiz de Azúa; Miguel Bernardo; Miquel Bioque; Bibiana Cabrera; Iluminada Corripio; Celso Arango; Antonio Lobo; Ana M Sánchez-Torres; Manuel J Cuesta
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.